Afimetoran for Lupus
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial is testing a new medication called Afimetoran to help people with active Systemic Lupus Erythematosus (SLE). The goal is to see if it can safely reduce symptoms by calming down the immune system. The study will also provide data on its effectiveness and safety over time.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
Is Afimetoran generally safe for humans?
How is the drug Afimetoran unique in treating lupus?
Afimetoran is unique because it targets and blocks Toll-like receptors 7 and 8, which are involved in the immune response that contributes to lupus. This mechanism is different from other treatments, as it aims to prevent the overactive immune response by inhibiting these specific receptors, potentially offering a new way to manage the disease.12367
What data supports the effectiveness of the drug Afimetoran for treating lupus?
Who Is on the Research Team?
Bristol-Myers Squibb
Principal Investigator
Bristol-Myers Squibb
Are You a Good Fit for This Trial?
This trial is for people with active Systemic Lupus Erythematosus (SLE) who meet specific criteria, including a positive test for certain lupus-related antibodies and a minimum disease activity score. It's not open to those with severe lupus nephritis, Antiphospholipid Syndrome, unstable neuropsychiatric symptoms, or if their main diagnosis isn't SLE.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive Afimetoran or placebo to evaluate effectiveness, safety, and tolerability
Follow-up
Participants are monitored for safety and effectiveness after treatment
Extension
Participants initially randomized to placebo may receive Afimetoran for additional long-term safety and efficacy data
What Are the Treatments Tested in This Trial?
Interventions
- Afimetoran
- BMS-986256 (Oral)
- Placebo
Find a Clinic Near You
Who Is Running the Clinical Trial?
Bristol-Myers Squibb
Lead Sponsor
Christopher Boerner
Bristol-Myers Squibb
Chief Executive Officer since 2023
PhD in Business Administration from the Haas School of Business, University of California, Berkeley; BA in Economics and History from Washington University in St. Louis
Deepak L. Bhatt
Bristol-Myers Squibb
Chief Medical Officer since 2024
MD from Yale University; MSc in Clinical Epidemiology from the University of Pennsylvania